Cargando…

Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer

Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate frequent copy number aberrations (CNAs). Here, we describe an integrative genomic and RNAi-based approach that identifies and validates gene addictions in TNBCs. CNAs and gene expression alterations are...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Nirmesh, Weekes, Daniel, Drosopoulos, Konstantinos, Gazinska, Patrycja, Noel, Elodie, Rashid, Mamun, Mirza, Hasan, Quist, Jelmar, Brasó-Maristany, Fara, Mathew, Sumi, Ferro, Riccardo, Pereira, Ana Mendes, Prince, Cynthia, Noor, Farzana, Francesch-Domenech, Erika, Marlow, Rebecca, de Rinaldis, Emanuele, Grigoriadis, Anita, Linardopoulos, Spiros, Marra, Pierfrancesco, Tutt, Andrew N. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849766/
https://www.ncbi.nlm.nih.gov/pubmed/29535384
http://dx.doi.org/10.1038/s41467-018-03283-z
Descripción
Sumario:Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but demonstrate frequent copy number aberrations (CNAs). Here, we describe an integrative genomic and RNAi-based approach that identifies and validates gene addictions in TNBCs. CNAs and gene expression alterations are integrated and genes scored for pre-specified target features revealing 130 candidate genes. We test functional dependence on each of these genes using RNAi in breast cancer and non-malignant cells, validating malignant cell selective dependence upon 37 of 130 genes. Further analysis reveals a cluster of 13 TNBC addiction genes frequently co-upregulated that includes genes regulating cell cycle checkpoints, DNA damage response, and malignant cell selective mitotic genes. We validate the mechanism of addiction to a potential drug target: the mitotic kinesin family member C1 (KIFC1/HSET), essential for successful bipolar division of centrosome-amplified malignant cells and develop a potential selection biomarker to identify patients with tumors exhibiting centrosome amplification.